SciClone Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 81   

Articles published

SCLN 8.86 -0.09 (-1.01%)
price chart
Why SciClone Pharmaceuticals, Inc. Is Surging Higher
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
SciClone Pharmaceuticals, Inc. (SCLN) Updates FY15 Earnings Guidance  Dakota Financial News
SciClone Pharmaceuticals Inc. (SCLN) Is Climbing On Q4 Results  RTT News
Fair Value for SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN)
SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) will report their fourth quarter earnings results on March 11. With that in mind, we look to see how the stock is priced based on current analyst expectations from a fundamental growth and value perspective.
SciClone Pharmaceuticals Inc. (SCLN) is Trading Higher on Unusual Volume for ...
SciClone Pharmaceuticals Inc. ($SCLN) experienced unusually high volume on Mar. 16, as the stock gained 1.85% to a closing price of $8.83.
SciClone Pharmaceuticals Inc. (SCLN) is Trading Lower on Unusual Volume for ...
SciClone Pharmaceuticals Inc. ($SCLN) experienced unusually high volume on Mar. 09, as the stock lost 3% to a closing price of $7.76.
Brokerage Firm Price Target on SciClone Pharmaceuticals, Inc.
Brokerage firm BWS Financial downgrades its rating on SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN). The shares have been rated Hold.
Update: SciClone Pharmaceuticals Exceeds Earnings Estimates For Q3 (SCLN)
What matters is that sales of the company's leading product, Zadaxin increased 28.4% to $32.1 million year-over-year. This shows that demand for the drug has increased at a strong pace.
Related articles »  
SciClone Pharmaceuticals' (SCLN) CEO Friedhelm Blobel on Q3 2014 Results ...
SciClone Pharmaceuticals' (SCLN) CEO Friedhelm Blobel on Q3 2014 Results - Earnings Call Transcript. Nov. 10, 2014 9:47 PM ET | About: SciClone Pharmaceuticals, Inc. (SCLN) by: SA Transcripts. SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN).
Related articles »  
SciClone Pharmaceuticals, Inc. (SCLN) Issues FY14 Earnings Guidance
SciClone Pharmaceuticals logo SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) updated its FY14 earnings guidance on Tuesday.
SciClone Pharmaceuticals Inc.: SciClone Reports 2014 Financial Results and ...
SciClone believes the restructuring has enabled the Company to better focus resources on potential high-growth areas, including its cardiovascular franchise.
SciClone Pharmaceuticals' (SCLN) CEO Friedhelm Blobel on Q4 2014 Results ...  Seeking Alpha (registration)
SciClone Reports 2014 Financial Results and 2015 Outlook  CNNMoney
Buy, Sell, or Hold: SciClone Pharmaceuticals Inc. (NASDAQ:SCLN)
SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) develops and commercializes novel medicines for treating a broad range of the world's most serious diseases.